RSS | Login | Register

Cefoxitin Injection

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare Cefoxitin Injection to:

Generic Name for Cefoxitin Injection

Cefoxitin sodium 1g, 2g; for IV inj; sodium content 2.3mEq/g.

Legal Classification:

Pharmacological Class for Cefoxitin Injection

Cephalosporin.

Manufacturer of Cefoxitin Injection

Various generic manufacturers

Indications for Cefoxitin Injection

Susceptible bacterial septicemia, lower respiratory or urinary tract, skin and skin structure, bone and joint, gynecologic, intraabdominal infections. Surgical prophylaxis.

Adult dose for Cefoxitin Injection

Usually 1–2g every 6–8 hrs. Uncomplicated: 1g every 6–8 hrs. Moderately severe to severe: 1g every 4 hrs or 2g every 6–8 hrs. Max 2g every 4 hrs or 3g every 6 hrs. Prophylaxis: see literature.

Children's dosing for Cefoxitin Injection

<3months: not recommended. ≥3months: 80-160mg/kg per day in 4–6 equal divided doses; max 12g/day. Prophylaxis: see literature.

Warnings/Precautions for Cefoxitin Injection

Penicillin or other allergy. Renal impairment (CrCl <50mL/min), reduce dose: see literature. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.

Interactions for Cefoxitin Injection

Aminoglycosides may potentiate nephrotoxicity. Potentiated by probenecid. May cause false (+) Clinitest. May interfere with creatinine tests.

Adverse Reactions for Cefoxitin Injection

Local reactions, rash, pruritus, drug fever, GI upset, anaphylaxis, blood dyscrasias, elevated liver enzymes.

How is Cefoxitin Injection supplied?

Contact supplier.

Related Disease:

Infections, bacterial~systemic antiinfectives

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.